Amylyx Pharmaceuticals, Inc.

AMLX

$117.60B

Large Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE123 employees

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Avexitide Phase 3 Results Expected

March 2026~Avexitide75

Primary completion for Avexitide trial (NCT06747468) in Post Bariatric Hypoglycemia

Source

⭐Phase 3

AMX0035 Phase 3 Results Expected

Apr 1, 2026AMX0035110

Primary completion for AMX0035 trial (NCT06122662) in Progressive Supranuclear Palsy

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

AMX0035

Phase 3

Amyotrophic Lateral Sclerosis

Avexitide

Phase 3

Post Bariatric Hypoglycemia

Drug Name	Phase	Indication	Designations
AMX0035	Phase 3	Amyotrophic Lateral Sclerosis	-
Avexitide	Phase 3	Post Bariatric Hypoglycemia	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

AMLX News